Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
Background: Genome editing offers unique perspectives for optimizing the functional properties of T cells for adoptive cell transfer purposes. So far, PDCD1 editing has been successfully tested mainly in chimeric antigen receptor T (CAR-T) cells and human primary T cells.
- Ref: DOI: 10.1136/jitc-2019-000311
- Année de publication : 2020
- Auteurs : Marotte L, Simon S, Vignard V, Dupre E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Shaffer J, Beauvais T, Gaschet J, Scotet E, Fradin D, Jarry A, Nguyen T, Labarriere N. J Immunother
- Réseaux : Réseaux: « Immunothérapies »